Get the Stockscreener App
1.44
5.26%
-0.08
After Hours:
1.44
Biovie Inc stock is traded at $1.44, with a volume of 202.13K.
It is down -5.26% in the last 24 hours and down -4.00% over the past month.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
See More
Previous Close:
$1.52
Open:
$1.58
24h Volume:
202.13K
Relative Volume:
2.53
Market Cap:
$10.86M
Revenue:
-
Net Income/Loss:
$-17.43M
P/E Ratio:
-0.3867
EPS:
-3.7237
Net Cash Flow:
$-14.32M
1W Performance:
+9.92%
1M Performance:
-4.00%
6M Performance:
-0.69%
1Y Performance:
+39.81%
1-Day Range:
$1.3901
$1.58
1-Week Range:
$1.31
$1.58
52-Week Range:
$0.88
$9.56
Biovie Inc Stock (BIVI) Company Profile
Name
Biovie Inc
Sector
Industry
Phone
775-888-3162
Address
680 W NYE LANE, CARSON CITY
Compare BIVI vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIVI
Biovie Inc
|
1.44 | 11.46M | 0 | -17.43M | -14.32M | -3.7237 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biovie Inc Stock (BIVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-15-21 | Initiated | B. Riley Securities | Buy |
Biovie Inc Stock (BIVI) Latest News
Small cap wrap: First Phosphate, Miivo Holdings, 1911 Gold, BioVie… - Proactive financial news
BioVie completes enrollment in Long COVID trial as need for treatments grows - Proactive financial news
BioVie completes enrollment in Phase 2 Long COVID trial - Proactive financial news
BioVie (BIVI) Completes Enrollment for Phase 2 Trial of Bezister - GuruFocus
BioVie completes enrollment in Long COVID treatment trial By Investing.com - Investing.com Canada
Long COVID patients await results as BioVie trial hits full enrollment - Stock Titan
BioVie Inc. (BIVI) Gains 2.7% as Shares Test Near-Term ResistanceCTA Positioning - Newser
BioVie Inc. (BIVI) Q1 2026 Earnings: Narrowing Losses and Clinical Progress Buoy Investor SentimentStrong Earnings Momentum - Newser
BioVie Inc.Common stock (NQ: BIVI - The Chronicle-Journal
BioVie Stock Pops After Parkinson’s Trial Milestone. The Real Test Comes in Q3 - Bez Kabli
BioVie (BIVI) Rallies +1.53% as Bulls Target $1.40 2026-05-20McClellan Summation - Newser
BioVie completes final patient visit in Parkinson's drug trial - Proactive financial news
BioVie (BIVI) Completes Patient Evaluations for Parkinson's Tria - GuruFocus
BioVie completes patient visits in Parkinson’s disease trial By Investing.com - Investing.com Nigeria
BioVie completes patient visits in Parkinson’s disease trial - Investing.com
BioVie Inc. Completes Final Patient Visit in SUNRISE-PD Phase 2 Trial for Bezisterim in Early-Stage Parkinson's Disease - Quiver Quantitative
Experimental Parkinson’s drug bezisterim finishes key trial, results due Q3 - Stock Titan
Why BioVie (BIVI) Just Surged +3.82% — Key Levels Ahead 2026-05-18Most Discussed Stocks - Newser
TradingKey - TradingKey
BioVie | 10-Q: Quarterly report - Moomoo
BIOVIE ($BIVI) Releases Q3 2026 Earnings - Quiver Quantitative
BioVie Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026 - marketscreener.com
[10-Q] BIOVIE INC. Quarterly Earnings Report - Stock Titan
BioVie nears data readout for potential first treatment targeting long COVID symptoms. - Pluang
BioVie CEO shares insights into long COVID trialICYMI - Proactive financial news
Why BioVie (BIVIW) leadership matters more than you think (Smart Money Outflows) 2026-05-08Analyst Recommended Stocks - newser.com
BioVie (BIVIW) quarterly earnings show no revenue or profit data, raising transparency concerns among market participants.Free Signal Network - Newser
Alumni StoriesCuong Do - Dartmouth Tuck School of Business
BioVie advances long COVID trial, top-line data expected by summer - Proactive financial news
12 Health Care Stocks Moving In Friday's After-Market SessionAkanda (NASDAQ:AKAN), BioVie (NASDAQ:BIVI - Benzinga
BioVie Investor Deadline Approaching - TMX Newsfile
What influences BioVie (BIVIW) stock price action |Crowd Sentiment Stocks - Newser
BioVie Shareholder Notice - TMX Newsfile
BIVIW Price History for Biovie WT Stock - Barchart.com
BioVie to host KOL event highlighting Bezisterim's potential in Parkinson's Disease - Proactive financial news
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026 - ChartMill
Why United Rentals Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Sahm
BioVie stock dips on pricing $12M securities offering - MSN
BioVie (BIVI) Market Position | Q3 2025: Better Than ExpectedCommunity Driven Stock Picks - Cổng thông tin điện tử tỉnh Tây Ninh
Is BioVie (BIVI) stock showing bullish signals today | BioVie Inc. Delivers 13.5 Percent EPS Beat Topping Analyst EstimatesTrending Entry Points - Cổng thông tin điện tử tỉnh Tây Ninh
BIVIW (BioVie) PS Ratio : (As of Apr. 27, 2026) - GuruFocus
BIVIW (BioVie) Cyclically Adjusted PB Ratio : (As of Apr. 22, 2026) - GuruFocus
BIVIW (BioVie) Cyclically Adjusted PS Ratio : (As of Apr. 27, 2026) - GuruFocus
BIVIW (BioVie) EV-to-EBIT : 0.00 (As of Apr. 22, 2026) - GuruFocus
BioVie Inc (BIVIW) Valuation - GuruFocus
BioVie Inc (BIVIW) Competitors 2026 - GuruFocus
BioVie Inc (BIVIW) Stock HoldersInstitutional & Insider Ownership - GuruFocus
Biovie Inc Stock (BIVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):